ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
August 13, 2013

UPDATE: Cancer Programme IPP-204106

Read More
August 12, 2013

FDA Grants ImmuPharma ammended SPA for Lupuzor Phase III; Company Progresses Development Activities

Read More
July 08, 2013

Appointment of Scientific Advisory Board

Read More
May 21, 2013

ImmuPharma secures £50M financing facility for Lupuzor Phase III

Read More
April 08, 2013

Immupharma gets Lupuzor research boost

Read More
February 28, 2013

ImmuPharma Commences Trading on the Stuttgart Stock Exchange

Read More
January 28, 2013

CNRS Confirms Lupuzor’sTM Effectiveness

Read More
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved